Design of experiments assisted the development of inclusion complexes of ramipril using hydrophilic carriers for enhancement of solubility and dissolution rate
DOI:
https://doi.org/10.1590/s2175-97902022e20203Keywords:
Ramipril; β-cyclodextrin; Inclusion complexes; I-optimal design; Solubility; X-RD; In-vitro drug releaseAbstract
The goal of the present study was to develop inclusion complexes and polymers dispersions of ramipril prepared by physical mixing, kneading, co-evaporation, and solvent evaporation methods to enhance drug solubility and dissolution rate, and thereby to reduce drug dose and side effects using selected hydrophilic carriers such as β-CD, PVP-K25, PEG 4000, and HPMC K100M. The prepared formulations were characterized for solubility and in-vitro drug release studies. The systematic optimization of formulations was performed using I-Optimal experimental design by selecting factors such as type of carriers (X1), drug: carrier ratio (X2), and method of preparation (X3), and response variables including percent yield (Y1), solubility (Y2), Carr’s index (Y3) and drug release in 30 min (Y4). Mathematical modeling was carried out using a quadratic polynomial model. The inclusion complex formulation (F27) was selected as an optimized batch by numerical desirability function and graphical optimization with the help of design space. The inclusion complex prepared by the co-evaporation method showed maximum drug solubility and released in pH 6.8 phosphate buffer compared to pure and other formulations. The inclusion complex is a feasible approach to improve the solubility, dissolution rate, bioavailability, and minimization of drugs’ gastrointestinal toxicity upon oral administration of ramipril.
Downloads
References
Alderman MH. Hypertension control: improved, but not enough! Am J Hypertens. 2007;20(4):347.
Aleksandra Z, Nuno R, Alessandra D, Massimo L, Nicola C, Soukaina EM, et al. Development and optimization of alpha-pinene-loaded solid lipid nanoparticles (SLN) using experimental factorial design and dispersion analysis. Molecules. 2019;24(15):2683.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-1252.
Duchene D, Wouessidjewe D. Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev Ind Pharm. 1990;16(17):2487-2499.
Ekambaram P, Abdul HS. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm. 2011;3(3):216-20.
Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instrum. 1965;4:117-212.
Kedzierrewicz F, Huffman M, Maincent P. Comparison of tolbutamide β-cyclodextrin inclusion compounds and solid dispersions: Physicochemical characteristics and dissolution studies. Int J Pharm. 1990;58(3):221-227.
Kim CK, Choi JY, Yoon YS, Gong JP, Choi HG, Kong JY, et al. Preparation and evaluation of a dry elixir for the enhancement of the dissolution rate of poorly water-soluble drugs. Int J Pharm . 1994;106(1):25-32.
Kislalioglu MS, Khan MA, Blount C, Goettsch RW, Bolton S. Physical characterization and dissolution properties of ibuprofen: Eudragit coprecipitates. J Pharm Sci. 1991;80(8):799-804.
Komati S, Swain S, Rao MEB, Jena BR, Dasi V. QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential. Bull Fac Pharm Cairo Univ. 2018;56(2):129-145.
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci . 2009;71(4):349-58.
Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-77.
Nambu N, Kikuchi K, Kikuchi T, Takahashi Y, Ueda H, Nagai T. Influence of inclusion of nonsteroidal antiinflammatory drugs with β-cyclodextrin on the irritation to stomach of rats upon oral administration. Chem Pharm Bull. 1978;26(12):3609-3612.
Parhi R, Reddy SS, Swain S. Transdermal delivery of ondansetron HCl from thermoreversible gel containing nanocomposite. Curr Nanometer. 2019;4(2):137-147.
Parhi R, Suresh P, Pattnaik S. Pluronic lecithin organogel (PLO) of diltiazem hydrochloride: effect of solvents/penetration enhancers on ex-vivo permeation. Drug Deliv Transl Res. 2016;6(3):243-253.
Patra CN, Swain S, Mohanty S, Panigrahi KC. Design and characterization of aceclofenac and paracetamol spherical crystals and their tableting properties. Powder Technol. 2015;274:446-454.
Rao MEB, Swain S, Patra CN, Jammula S, Patra S. Development and in vitro evaluation of floating multiparticulate system of repaglinide. FABAD J Pharm Sci . 2011;36(2):75-92.
Sugawara M, Kadomura S, Xin H, Takekuma Y, Khori N, Miyazaki K. The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations. Eur J Pharm Sci . 2005;26(1):1-8.
Swain S, Behera A, Dinda SC, Patra CN, Jammula S, Beg S, et al. Formulation design, optimization and pharmacodynamic evaluation of sustained release mucoadhesive microcapsules of venlafaxine HCl. Indian J Pharm Sci . 2014;76(4):267-378.
Swain S, Behera UA, Beg S, Sruti J, Patro CN, Dinda SC, et al. Design and characterization of enteric-coated controlled release mucoadhesive microcapsules of rabeprazole sodium. Drug Dev Ind Pharm . 2012;39(4):548-60.
Swain S, Sahu PK, Jena BR, Beg S, Babu SM. Formulation development, statistical optimization and characterization of the self-microemulsifying drug delivery system (SMEDDS) of irbesartan. Nanosci Nanotechnol-Asia. 2019;9(2):210-228.
Szejtli J. Cyclodextrin in drug formulations: Part II. Pharm Tech. 1991;24-38.
Yoshida A, Arima H, Uekama K, Pitha J. Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrin. Int J Pharm . 1988;46(3):217-222.
Youn YS, Tung JYS, Yoo SD, Lee KC. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Contr Rel. 2006;144(3):334-42.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
